Carvedilol Tablet, Film Coated
Product Images NDC 68001-152

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 68001-152). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carvedilol Tablets 3.125mg 100 Tablets Rev 0913 (8d2c4ed7 9a51 4dc4 B914 0b5ef8242de1 04)

Carvedilol Tablets 3.125mg 100 Tablets Rev 0913 (8d2c4ed7 9a51 4dc4 B914 0b5ef8242de1 04)
Carvedilol Tablets, USP 3.125 mg film-coated tablets label from BluePoint Laboratories. The label shows two round tablets marked with '1' and '2', a quantity of 100 tablets, and detailed storage and safety instructions. The NDC is 68001-153-00 and the label indicates prescription use only.*
FDA Label Image

Carvedilol Tablets 6.25mg 100 Tablets Rev 0913 (8d2c4ed7 9a51 4dc4 B914 0b5ef8242de1 05)

Carvedilol Tablets 6.25mg 100 Tablets Rev 0913 (8d2c4ed7 9a51 4dc4 B914 0b5ef8242de1 05)
Carvedilol Tablets USP 6.25 mg film-coated tablets label by BluePoint Laboratories. The label shows a single white round tablet with imprint, NDC 68001-154-00, and states the package contains 100 tablets. Instructions include storage temperature, dispensing warnings, and strength information.*
FDA Label Image

Carvedilol Tablets 12.5mg 100 Tablets Rev 0913 (8d2c4ed7 9a51 4dc4 B914 0b5ef8242de1 06)

Carvedilol Tablets 12.5mg 100 Tablets Rev 0913 (8d2c4ed7 9a51 4dc4 B914 0b5ef8242de1 06)
Label for Carvedilol Tablets, USP 12.5 mg film-coated oral tablets by BluePoint Laboratories. The label includes a white round tablet imprint "ZC41", NDC 68001-151-00, with storage and dispensing instructions. The package contains 100 tablets, manufactured by Cadila Healthcare Ltd., India for BluePoint Laboratories.*
FDA Label Image

Carvedilol Tablets 25mg 100 Tablets Rev 0913 (8d2c4ed7 9a51 4dc4 B914 0b5ef8242de1 07)

Carvedilol Tablets 25mg 100 Tablets Rev 0913 (8d2c4ed7 9a51 4dc4 B914 0b5ef8242de1 07)
Packaging label for Carvedilol Tablets USP, 25 mg film-coated tablets, with a package count of 100 tablets. The label shows the BluePoint Laboratories logo and indicates the product is manufactured by Cadila Healthcare Ltd. for BluePoint Laboratories. The label includes storage, safety, and dispensing instructions.*
FDA Label Image

Structured Formula For Carvedilol (Image 01)

Structured Formula For Carvedilol (Image 01)
Chemical structure of carvedilol, showing its molecular components including aromatic rings, hydroxyl groups, and an ether linkage, corresponding to the active ingredient carvedilol.*
FDA Label Image

Structured Formula For Carvedilol (Image 02)

Structured Formula For Carvedilol (Image 02)
A line graph comparing percentage mortality over a 24-month period between Carvedilol and a placebo. The y-axis represents percentage mortality, and the x-axis shows months elapsed. The graph indicates lower mortality percentages for Carvedilol compared to placebo over time, with a p-value of 0.03 noted.*
FDA Label Image

Structured Formula For Carvedilol (Image 03)

Structured Formula For Carvedilol (Image 03)
A forest plot chart depicting hazard ratios with confidence intervals for various patient subgroups including age, gender, time since myocardial infarction, beta-blocker usage, Killip class, thrombolytic use, PTCA, congestive heart failure status, angina, hypertension, diabetes, heart rate, and systolic blood pressure. The plot compares hazard ratios around 1.0 for these different clinical variables in a medical study context.*
FDA Label Image

Figure 1 (Image 04)

Figure 1 (Image 04)
A line graph comparing mortality percentages over a 24-month period between two groups: Placebo and Carvedilol. The vertical axis represents % mortality, ranging from 0 to 30, and the horizontal axis represents time in months. The Carvedilol group shows lower mortality compared to Placebo, with a p-value of 0.0014 indicated.*
FDA Label Image

Figure 2 (Image 05)

Figure 2 (Image 05)
A forest plot illustrating hazard ratios across various subgroups including sex, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure, and spironolactone use. Each subgroup is represented with a point estimate and confidence intervals, with a vertical line at hazard ratio 1.0 indicating no effect. The chart includes an overall estimate for all patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.